Proactive - Interviews for investors
Futura Medical CEO James Barder on Futura’s 2024 strong growth, maiden profit and 2025 plans
Futura Medical PLC CEO James Barder takes Proactive's Stephen Gunnion through the company’s 2024 financial performance, market expansion and product pipeline.
Futura reported a strong year in 2024, with CEO Barder highlighting revenue of £14 million and a maiden profit of £1.3 million—or £3.3 million excluding non-cash items. Barder noted that Eroxon is now sold in over 15 countries and is expected to reach over 20 by the end of 2025. “2024 was a very good year for us,” he said.
Barder emphasised the company’s commitment to supporting commercial partners and building momentum behind its flagship product, Eroxon. He explained that markets seeing the most success were those effectively targeting men under 60 with mild to moderate erectile dysfunction—Eroxon’s most responsive user group.
The conversation also touched on upcoming products, including Eroxon Intense, a variant delivering a stronger sensory experience, and SD4000, a topical treatment for female sexual dysfunction. Barder noted that 87% of women in clinical trials for SD4000 wished to continue use post-study—an encouraging sign.
Looking ahead, Barder said the company will continue expanding its presence, drive forward its pipeline, and focus on areas it can control, despite share price frustrations.
For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and hit the bell icon for updates.
#FuturaMedical #Eroxon #EroxonIntense #SD4000 #ErectileDysfunction #FemaleHealth #PharmaNews #OTCProducts #HealthcareInnovation #BiotechUpdate